10.21
+0.1994(+1.99%)
Currency In USD
| Previous Close | 10.01 |
| Open | 10.01 |
| Day High | 10.24 |
| Day Low | 10.01 |
| 52-Week High | 10.34 |
| 52-Week Low | 6.69 |
| Volume | 489,932 |
| Average Volume | 1.57M |
| Market Cap | 3.21B |
| PE | 1,020.5 |
| EPS | 0.01 |
| Moving Average 50 Days | 9.17 |
| Moving Average 200 Days | 8.26 |
| Change | 0.2 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $680.17 as of October 01, 2025 at a share price of $10.209. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $2,545.99 as of October 01, 2025 at a share price of $10.209.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal to Report Third Quarter 2025 Results on October 30, 2025
GlobeNewswire Inc.
Yesterday at 8:05 PM GMT
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial result
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
GlobeNewswire Inc.
Sep 26, 2025 12:00 PM GMT
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for AmnealBRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced t
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
GlobeNewswire Inc.
Sep 23, 2025 12:00 PM GMT
Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segmentBRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announc